Stevens Christopher James 4

What Happened Christopher J. Stevens, Chief Operating Officer of Rocket Pharmaceuticals, was granted equity awards on February 11, 2026: 61,963 restricted stock units (RSUs) and a derivative grant representing the right to acquire 93,037 shares. Both entries are reported as acquired at $0.00 in the Form 4 (i.e., grants/awards rather than open‑market purchases or sales).

Key Details

• Transaction date: 2026-02-11; Filing date: 2026-02-13 (timely filing).
• Grants reported: 61,963 RSUs (award A) and a derivative grant for 93,037 shares (award A), both with acquisition price $0.00.
• Shares owned after transaction: not explicitly stated in the provided filing excerpt; note F1 indicates holdings include RSUs that convert one-for-one to common stock.
• Vesting / footnotes:
  • F2 (RSUs): 1/3 vests on Feb 11, 2027; remaining shares vest in equal quarterly installments over the next two years.
  • F3 (option/derivative): the 93,037-share right vests on the same schedule — 1/3 on Feb 11, 2027, then quarterly over two years, subject to continued employment.
• No indication of immediate sale or cashless exercise in this filing.

Context These are compensation awards (RSUs and a time‑vesting option-like grant) rather than purchases or sales. RSUs convert to common shares 1:1 when vested; the derivative grant represents the right to purchase shares upon vesting. Such grants are routine for executive compensation and do not by themselves indicate trading sentiment.